Janssen Search
Search results
New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
Mar 05, 2023 United States Findings presented at ACC.23 show XARELTO ® plus aspirin provides a 33 percent reduction in acute limb ischemia following LER, with consistent benefit demonstrated at 30 days, 90 days and up to three years Patients who undergo ...
Janssen Submits New Drug Application to U.S. FDA Seeking Approval of Investigational Single Tablet Combination Therapy of Macitentan and Tadalafil for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)
May 30, 2023 United States This is the first and only single tablet combination therapy application to be submitted for review in the U.S. for this rare, progressive disease If approved, Janssen’s comprehensive PAH portfolio has the potential to cover all ...
Better Medicines, Healthier Communities: Improving Health Equity in Cancer Clinical Trials
Better Medicines, Healthier Communities: Improving Health Equity in Cancer Clinical Trials The Johnson & Johnson Our Race to Health Equity initiative aims to help increase access to health care, including clinical trials, for underserved and ...
Facing the alarming truth about AMR
Facing the alarming truth about AMR 3D- render of a germ bacteria under a microscope My journey as a scientist was born out of a lifelong fascination with bacteria, their biology, and their biochemistry as the smallest and earliest forms of life on earth. ...
Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression
Jul 22, 2024 Phase 4 SPRAVATO® monotherapy data shows rapid improvement in depressive symptoms at ~24 hours, sustained through at least 4 weeks Monotherapy submission builds on more than a decade of research, 31 clinical trials and more than five years of ...
Janssen Demonstrates Commitment to Transform the Treatment of Multiple Myeloma through Innovative Science and Industry-Leading Portfolio with Largest-Ever Presence at 20th International Myeloma Society Annual Meeting
Sep 27, 2023 United States Presentations to highlight latest data across biologic, bispecific and CAR-T therapies with added insights from Global Multiple Myeloma Call-to-Action RARITAN, N.J., September 27, 2023 — The Janssen Pharmaceutical Companies ...
Science and Art Help End Stigma About Mental Illness
Science and Art Help End Stigma About Mental Illness Jun 26, 2018 Globally, one person in four will develop a mental or neurological disorder at some point in his or her life. 1 Despite such a high prevalence, stigma – shame or disgrace – about mental ...
The IL-23 Pathway: Defining a New Paradigm in Immunology
The IL-23 Pathway: Defining a New Paradigm in Immunology The discovery of the IL-23 pathway and elucidation of its role in autoimmunity has led to a paradigm shift within the field of immunology. Decades ago, T cells were divided into CD4+ helper and CD8+ ...
Sexual and Gender Minority Health Equity in Prostate Cancer Care
Sexual and Gender Minority Health Equity in Prostate Cancer Care For decades, researchers, healthcare professionals, patients and their loved ones have come together to advance treatment and care for people diagnosed with prostate cancer. Clinical ...
Our Commitment to Rheumatology
About Rheumatoid Arthritis Rheumatoid arthritis (RA) is a chronic, symmetric, inflammatory disease involving the synovial joints, where bone and cartilage erosion lead to irreversible joint damage. 1 Despite advancements in treatments, 20 to 30 percent of ...